John Hubbard ’78 has been appointed CEO of BioClinica, a leading provider of specialty outsourced clinical trial services. He is also a member of the company’s board of directors. A seasoned pharmaceutical executive, Dr. Hubbard, 58, will join the company from Pfizer Inc., where he has served as senior vice president and worldwide head of development operations. During his 30-year career, Dr. Hubbard has spearheaded pharmaceutical research and development initiatives for some of the industry’s premier organizations.  At Pfizer, he was responsible for more than 450 Phase 1-4 clinical projects per year.  He also served on the taskforce that redesigned Pfizer’s research and development organization.

 

Prior to Pfizer, Dr. Hubbard was group president of ICON plc’s clinical research services business, the company’s largest business division. During his tenure, ICON was named one of the country’s fastest growing companies by FORTUNE.  Dr. Hubbard also has held management positions at PAREXEL International Corporation, Revlon Health Care Group and Hoechst Marion Roussel Pharmaceuticals (now owned by Sanofi).

 

 

Dr. Hubbard is a member of the Society of Clinical Pharmacology and Therapeutics, Drug Information Association and has served on its Special Interest Advisory Committee on Project Management.  He is a board certified diplomat in applied pharmacology and was elected as a fellow of the American College of Clinical Pharmacology (ACCP).  Dr. Hubbard has authored and co-authored articles and chapters on biopsychology, cardiovascular, clinical pharmacology and global drug development.  He received his bachelor’s degree in biopsychology from the University of Santa Clara and a doctorate from the University of Tennessee.  Dr. Hubbard was a National Institute of Health postdoctoral fellow in cardiovascular and clinical pharmacology at the University of Texas Health Sciences Center.